Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954796 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL14566205 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL5591019 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL5590917 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL5590918 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL901102 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL5591022 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL112671 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| Alpha-Ionone SCHEMBL112670 | 0.87 | ALDH1A1 (0.71) | ALDH1A1CYP3A4ALOX15TDP1KDM4E | |
| SCHEMBL12493700 | 0.87 | ALDH1A1 (0.63) | ALDH1A1CYP3A4ALOX15TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2417095-B1 | CARBOXYLIC DERIVATIVES AS VIOLET AND/OR WOODY ODORANT | FIRMENICH & CIE (CH) | 2015-01-14 | — | — | EP | disclosed |
| US-8183194-B2 | Carboxylic derivatives as violet and/or woody odorant | FIRMENICH SA (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-7947687-B2 | 1,7-Bis-(2,6,6-trimethylcyclohex-1-en-1-yl)-1 (E)-heptadiene-3,5-dione, analogs and derivatives thereof for treating cancer; potent inhibitory effect on the proliferation of human promyelocyte leukemia HL-60 cells | ROBINSON BYRON C | 2011-05-24 | — | — | US | disclosed |
| US-7947687-B2 | 1,7-Bis-(2,6,6-trimethylcyclohex-1-en-1-yl)-1 (E)-heptadiene-3,5-dione, analogs and derivatives thereof for treating cancer; potent inhibitory effect on the proliferation of human promyelocyte leukemia HL-60 cells | ROBINSON BYRON C | 2011-05-24 | — | — | US | disclosed |
| US-7947687-B2 | 1,7-Bis-(2,6,6-trimethylcyclohex-1-en-1-yl)-1 (E)-heptadiene-3,5-dione, analogs and derivatives thereof for treating cancer; potent inhibitory effect on the proliferation of human promyelocyte leukemia HL-60 cells | ROBINSON BYRON C | 2011-05-24 | — | — | US | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | ROBINSON BYRON C | 2008-08-21 | — | — | US | disclosed |
| WO-2007098118-A9 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007098118-A9 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007098118-A2 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007098118-A2 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BYRON ROBINSON PHARMACEUTICAL, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | ALDH1A1 2958/4885CYP3A4 4674/4885ALOX15 4274/4885 |
| US-20080200478-A1 | ANTINEOPLASTIC AND CURCUMIN DERIVATIVES AND METHODS OF PREPARATION AND USE | BCL3, CASP3, MCL1 | ALDH1A1 361/4885CYP3A4 573/4885ALOX15 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.